108 related articles for article (PubMed ID: 21312324)
1. Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent patients.
Cohen IJ
Pediatr Blood Cancer; 2011 Jul; 56(7):1151. PubMed ID: 21312324
[No Abstract] [Full Text] [Related]
2. Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.
Shah AC; Kelly DR; Nabors LB; Oakes WJ; Hilliard LM; Reddy AT
Pediatr Blood Cancer; 2010 Dec; 55(6):1227-30. PubMed ID: 20882580
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma.
Green MR; Chowdhary S; Lombardi KM; Chalmers LM; Chamberlain M
Expert Rev Neurother; 2006 May; 6(5):635-52. PubMed ID: 16734512
[TBL] [Abstract][Full Text] [Related]
4. [II. Primary treatment of CNS lymphoma with high-dose MTX].
Iwadate Y
Gan To Kagaku Ryoho; 2012 Jun; 39(6):892-7. PubMed ID: 22880222
[No Abstract] [Full Text] [Related]
5. Ogilvie's syndrome during chemotherapy with high-dose methotrexate for primary CNS lymphoma.
Xie H; Peereboom DM
J Clin Oncol; 2012 Jul; 30(21):e192-4. PubMed ID: 22711852
[No Abstract] [Full Text] [Related]
6. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
7. How important is whole brain radiotherapy for treatment of primary CNS lymphoma?
Cabanillas F
Lancet Oncol; 2010 Nov; 11(11):1011-2. PubMed ID: 20970379
[No Abstract] [Full Text] [Related]
8. Primary central nervous system (CNS) lymphoma in immunocompetent patients.
Plasswilm L; Herrlinger U; Korfel A; Weller M; Küker W; Kanz L; Thiel E; Bamberg M
Ann Hematol; 2002 Aug; 81(8):415-23. PubMed ID: 12223997
[TBL] [Abstract][Full Text] [Related]
9. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.
Herrlinger U; Küker W; Uhl M; Blaicher HP; Karnath HO; Kanz L; Bamberg M; Weller M;
Ann Neurol; 2005 Jun; 57(6):843-7. PubMed ID: 15929034
[TBL] [Abstract][Full Text] [Related]
10. Systemic anaphylactic reaction following intrathecal administration of methotrexate in adult patient with primary central nervous system lymphoma.
Elkiran ET; Altundag K; Aksoy S; Onal IK; Tekuzman G
Am J Hematol; 2004 Apr; 75(4):265. PubMed ID: 15054831
[No Abstract] [Full Text] [Related]
11. Non-Hodgkin's lymphoma and the CNS: prophylaxis and therapy in immunocompetent and HIV-positive individuals.
Mazhar D; Stebbing J; Bower M
Expert Rev Anticancer Ther; 2006 Mar; 6(3):335-41. PubMed ID: 16503851
[TBL] [Abstract][Full Text] [Related]
12. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG).
O'Brien PC; Roos DE; Liew KH; Trotter GE; Barton MB; Walker QJ; Poulsen MG; Olver IN
Med J Aust; 1996 Oct; 165(8):424-7. PubMed ID: 8913243
[TBL] [Abstract][Full Text] [Related]
13. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
[TBL] [Abstract][Full Text] [Related]
14. [Primary central nervous system lymphoma: diagnosis, management and current topics].
Arita N
No To Shinkei; 2004 Mar; 56(3):195-203. PubMed ID: 15112444
[No Abstract] [Full Text] [Related]
15. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.
Illerhaus G; Müller F; Feuerhake F; Schäfer AO; Ostertag C; Finke J
Haematologica; 2008 Jan; 93(1):147-8. PubMed ID: 18166803
[TBL] [Abstract][Full Text] [Related]
16. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate.
Reni M; Mazza E; Foppoli M; Ferreri AJ
Cancer Lett; 2007 Dec; 258(2):165-70. PubMed ID: 17993246
[TBL] [Abstract][Full Text] [Related]
17. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
[TBL] [Abstract][Full Text] [Related]
18. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Plotkin SR; Betensky RA; Hochberg FH; Grossman SA; Lesser GJ; Nabors LB; Chon B; Batchelor TT
Clin Cancer Res; 2004 Sep; 10(17):5643-6. PubMed ID: 15355887
[TBL] [Abstract][Full Text] [Related]
20. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
